Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

RFK Jr.'s comments about the gene-editing technology raise a question about how he would regulate it as head of HHS.

Visualizing cells after editing specific genes can help scientists learn new details about the function of those genes. But ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Robert F. Kennedy Jr. will be pulling his investments from two biotechs if he is confirmed to lead the U.S. Department of ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

As translational CRISPR-based research continues to make waves in laboratories and the clinic, scientists across life science disciplines pursue out-of-the-ordinary genome editing applications. From ...